BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...

A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Phase I evaluation of the PI3 kinase (PI3K) inhibitor ...

Secondary BRAF variations have been identified as a mechanism of resistance to tyrosine kinase inhibitors (TKIs) in patients with driver gene-positive NSCLC. Nevertheless, there is still a lack of ...

IMspire150 is a Phase III, multi-center, double-blind, placebo-controlled randomized study in people with previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Brain metastasis from melanoma is particularly deadly and options are limited due to the difficulty of breaching the brain-blood barrier. Recent research illustrated the potent and prolonged antitumor ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib ...

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers. The Food and Drug ...

“The relapse-free survival curves for both treatment arms appear to be reaching a plateau, which is a good sign if we are talking about cure,” said lead study author Dr. Axel Hauschild. Adjuvant ...